CPIXHealthcare · Drug Manufacturers - Specialty & Generic

CPIX Stock Forecast: Cumberland Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$6.39

−1.39% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 12 Sept 2026 — inside the top quartile.

Market cap

$95.7M

Ticker Nerd rank

84 / 100

Median analyst target

—

Analysts covering

Revenue$166K−98.5% y/y

Operating income−$3.2M

Net income−$4.3M

Free cash flow−$1.6M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−5.3%

−19.7%

YTD

+91.4%

+122.1%

From 52W high

−28.8%

From 52W low

+301.0%

$1.59

$8.97

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

CPIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cumberland Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Momentum

Issuance

Quality

Size

Value

Volatility

Revisions

Growth

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CPIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CPIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

0 Buy1 Hold0 Sell

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
3 Dec 2019	B. Riley	Maintains	Buy	—
3 Dec 2019	B. Riley Securities	Maintains	Buy	$9.00 → $9.75
18 Nov 2019	B. Riley FBR	Maintains	Buy	—
18 Nov 2019	B. Riley Securities	Maintains	Buy	—
17 Aug 2018	B. Riley FBR	Maintains	Buy	—
17 Aug 2018	B. Riley Securities	Maintains	Buy	—
5 May 2018	B. Riley FBR	Initiates	Buy	—
17 Apr 2018	B. Riley FBR	Initiates	Buy	—
17 Apr 2018	B. Riley Securities	Initiates	Buy	—
10 Apr 2013	UBS	Maintains	Neutral	—
12 Nov 2012	UBS	Maintains	Neutral	—
9 Nov 2012	Wells Fargo	Downgrade	Market Perform	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CPIX appears on the weeks it earns a place.

Performance

CPIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Cumberland Pharmaceuticals, Inc. returned +122.1% against +17.5% for the S&P 500, dividends included.

CPIX vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CPIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Cumberland Pharmaceuticals, Inc. (CPIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −33.9×
Price / sales: 2.2×
Price / book: 5.5×
EV / EBITDA: 87.8×

Growth & margins

Revenue growth (YoY): −56.3%
Earnings growth (YoY): −98.5%
Gross margin: 78.8%
Operating margin: −1898.7%
Net margin: −24.6%

Returns & dividend

Return on equity: −14.4%
Return on assets: −2.9%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cumberland Pharmaceuticals, Inc. (CPIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Cumberland Pharmaceuticals, Inc. has a market value of $95.7M and an enterprise value of $96.3M.
Revenue in the twelve months to 30 June 2026: $31.3M. The latest quarter shrank 56.3% year on year.
Net income over the same four quarters: −$10.9M, a −35.0% net margin.
Diluted earnings per share, trailing twelve months: $−0.71.
Free cash flow in the twelve months to 30 June 2026: −$1.2M.
Cumberland Pharmaceuticals, Inc. spent $71K on share buybacks in the twelve months to 30 June 2026.
Shares outstanding: 15.0M.
Trailing P/E: −33.9×; forward P/E: 45.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Cumberland Pharmaceuticals, Inc. employs 88 people — $355K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

CPIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
CPIXCumberland Pharmaceuticals, Inc.	$95.7M	84
CTORCitius Oncology, Inc.	$85.3M	18
BGMBGM Group Ltd.	$110.6M	41
ADCTADC Therapeutics SA	$132.5M	74
INCRInterCure Ltd.	$62.3M	9
TLPHTalphera, Inc.	$62.1M	42
OGIOrganigram Global, Inc.	$149.0M	41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cumberland Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CPIX news & analysis

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity

Seeking Alpha · 13 Aug 2026neutral

Cumberland Pharmaceuticals sold a $100M asset to Apotex, funded operations and paid a special dividend, while pivoting from a commercial-stage pharma to a pre-revenue Phase 2 biotech focused on rare diseases, retaining four late-stage ifetroban-based programs.

Why it matters — A CPIX watcher would care because the company's transformation into a pre-revenue biotech with a single-drug pipeline creates both potential upside from high-value indications and significant risk without current product sales.

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

The Q2 2026 earnings call transcript for Cumberland Pharmaceuticals Inc. (CPIX) was published on Seeking Alpha. The transcript covers the company's second-quarter 2026 earnings discussion.

Why it matters — A CPIX watcher would care because the transcript offers insight into the company's latest quarterly performance and management commentary.

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 4 Aug 2026negative

Cumberland Pharmaceuticals reported a second-quarter operating loss of $3.1 million as it prepares to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business after selling its U.S. branded commercial portfolio to Apotex Health.

Why it matters — A CPIX watcher would care because the operating loss marks a significant financial milestone as the company undergoes a major strategic transformation following the sale of its core commercial portfolio.

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

PRNewsWire · 4 Aug 2026positive

Cumberland Pharmaceuticals reported its Q2 2026 financial results and provided a company update following the closing of its $100 million Strategic Transaction with Apotex Health. The update also noted that a special shareholder dividend has been funded and that the company is advancing its late-stage clinical pipeline.

Why it matters — A CPIX watcher would care because the closed strategic transaction, funded special dividend, and advancing late-stage clinical pipeline reflect tangible milestones for the company's near-term financial and development outlook.

Possible Generic Drug Tariffs and 2 Microcaps

Zacks Investment Research · 31 July 2026neutral

A Zacks Investment Research article notes that possible tariffs on generic drugs could impact Cumberland Pharmaceuticals (CPIX), along with another microcap, ELTP.

Why it matters — CPIX investors may want to monitor generic drug tariff developments, as such policy changes could affect the company's operations or competitive position.

FAQ

Frequently asked questions about CPIX stock

Is CPIX stock a buy right now?

Of the 1 analysts covering Cumberland Pharmaceuticals, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cumberland Pharmaceuticals, Inc. 84 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CPIX?

As at 12 Sept 2026, Cumberland Pharmaceuticals, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

What is the CPIX stock forecast for 2030?

No analyst covering Cumberland Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CPIX are extrapolating price history, which says nothing about the business.

How has CPIX stock performed over the past year?

Cumberland Pharmaceuticals, Inc. returned +122.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cumberland Pharmaceuticals, Inc. do?

What is the latest news on CPIX?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity". Cumberland Pharmaceuticals sold a $100M asset to Apotex, funded operations and paid a special dividend, while pivoting from a commercial-stage pharma to a pre-revenue Phase 2 biotech focused on rare diseases, retaining four late-stage ifetroban-based programs.

Company

About Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing branded prescription medicines for hospital acute care and other specialized treatment settings. Cumberland Pharmaceuticals markets a portfolio of approved products used in areas such as pain and fever management, nausea and vomiting prevention, constipation, hyponatremia, and certain bacterial infections. Its business centers on delivering therapies for physicians, hospitals, and patients who need targeted prescription treatments in areas where standard options may be limited or highly specialized. The company also operates in therapeutic markets including gastroenterology, oncology support, and critical care, reflecting its emphasis on products used in acute and hospital-based care. Cumberland Pharmaceuticals plays a niche role in the healthcare market by focusing on prescription medicines designed for specific clinical needs rather than broad consumer health products.

CEO Mr. A. J. Kazimi MBA · 88 employees · United States · https://www.cumberlandpharma.com